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rancesco Prati, MD,* Sonia Petronio, MD,‡ Ad J. Van Boven, MD,¶
ichal Tendera, MD,# Leonardo De Luca, MD,† Mark A. de Belder, MD,††
lfredo R. Galassi, MD,§ Fabrizio Imola, MD,* Gilles Montalescot, MD,‡‡
an Z. Peruga, MD,** Elliot S. Barnathan, MD,§§ Stephen Ellis, MD, 
tefano Savonitto, MD, on behalf of the FINESSE-ANGIO Substudy Investigators
ome, Pisa, Catania, and Milan, Italy; Leeuwarden, Netherlands; Katowice and Lodz, Poland;
iddlesbrough, United Kingdom; Paris, France; Malvern, Pennsylvania; and Cleveland, Ohio
bjectives The FINESSE-ANGIO (Facilitated Intervention with Enhanced Reperfusion Speed to Stop
vents–Angiographic) study evaluated acute treatment effects on infarct-related artery (IRA) patency
nd angiographic correlates of coronary microcirculatory function.
ackground The FINESSE trial evaluated the effects on clinical outcomes of primary percutaneous coro-
ary intervention (PCI) facilitated with pre–catheterization laboratory administration of abciximab with
alf-dose reteplase (combination-facilitated group), abciximab alone (abciximab-facilitated group), or with
bciximab administered immediately before the procedure (primary PCI).
ethods The FINESSE-ANGIO substudy compared the effects of the 3 treatment strategies on pa-
ency (TIMI [Thrombolysis In Myocardial Infarction] ﬂow grade 2/3) of the IRA at basal coronary an-
iography. The secondary efﬁcacy end points were corrected TIMI frame count, percentage of pa-
ients achieving TIMI ﬂow grade 3, and the percentage achieving myocardial blush grade 2/3 of the
RA at post-PCI angiography. All angiographies were evaluated at a central core laboratory.
esults Of the 2,452 FINESSE patients, 637 were included in the FINESSE-ANGIO substudy. Patients
n the combination-facilitated group exhibited signiﬁcantly higher rates of baseline IRA patency
ompared with the abciximab-facilitated and the primary PCI groups (76.1% vs. 43.7% and 32.7%,
espectively; p  0.0001 for both; p  0.025 abciximab-facilitated vs. primary PCI). There were no
igniﬁcant differences in the post-PCI corrected TIMI frame count (17.1  15.8, 17.4  17.3, and 15.8
14.1) or the rates of post-PCI TIMI ﬂow grade 3 (79.8%, 77.7%, and 76.6%), myocardial blush
rade 2/3 (85.6%, 79.5%, and 86.4%), respectively.
onclusions Pre–catheterization laboratory administration of abciximab alone and especially in
ombination with half-dose reteplase resulted in higher rates of IRA patency at baseline coronary
ngiography compared with no pre-treatment. However, post-procedural angiographic and microcir-
ulatory variables were unaffected by facilitation therapy. (J Am Coll Cardiol Intv 2010;3:1284–91)
2010 by the American College of Cardiology Foundation
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1285t is well established that any delay in reperfusion therapy
uring ST-segment elevation myocardial infarction
STEMI) can limit the benefit of either thrombolysis (1–3)
r primary percutaneous coronary intervention (PCI) (4–6).
n addition, even successful recanalization of the infarct-
elated artery (IRA) may not result in reperfusion of the
oronary microcirculation, that is, of the myocardium, due
o mechanisms that are still not completely understood but
nclude embolization of thrombotic material from the
reated lesion, adhesion of platelets and leukocytes to the
njured endothelium, and inflammation and acute myocar-
ial ischemia (7).
See page 1292
Previous studies have shown that early administration of
bciximab, a glycoprotein (GP) IIb/IIIa inhibitor, enhances
RA patency (8–11). Angiographic studies in patients with
TEMI (12) have shown that the combination of a GP
Ib/IIIa blocker and fibrinolytic agent increases the IRA
IMI (Thrombolysis In Myocardial Infarction) flow grade
at 60 and 90 min compared with fibrinolytic therapy
lone. Other reports revealed improved microcirculatory
erfusion as assessed by myocardial blush grade (MBG and
T-segment resolution) (13,14).
The FINESSE (Facilitated Intervention with Enhanced
eperfusion Speed to Stop Events) study was designed to
valuate the effects on clinical outcomes at 90 days after the
mmediate administration of abciximab in conjunction with
alf-dose reteplase or abciximab alone before PCI, com-
ared with primary PCI with post-angiography abciximab
dministration in the catheterization laboratory in patients
ith STEMI with an expected delay to angioplasty of at
east 60 min (15). No significant reduction in the 90-day
rimary ischemic end point was seen with either facilitated
pproach, although nonsignificant favorable trends with facil-
tation therapy were seen for some patient subgroups (16).
This FINESSE-ANGIO study is a substudy of FINESSE
esigned to evaluate the acute effects of the 3 aforementioned
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zienda Ospedaliera Pisana, University of Pisa, Pisa, Italy; §Department of Cardi-
logy, Ferrarotto Hospital and University of Catania, Catania, Italy; “Angelo De
asperis” Department of Cardiology, Ospedale Niguarda CA’Granda, Milan, Italy;
Medisch Centrum Leeuwarden, Afdeling Hartcatheterisatie, Leeuwarden, Nether-
ands; #Slaski Uniwersytet Medyczny w Katowicach, Katowice, Poland; **Klinika
ardiologii IMW Uniwersytetu Medycznego, Lodz, Poland; ††the James Cook
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areatments on IRA patency and angiographic correlates of
oronary microcirculatory function.
ethods
tudy design. The FINESSE-ANGIO study’s patients in-
luded FINESSE participants from 6 countries (Italy,
rance, United Kingdom, Spain, the Netherlands, and
oland). Eligibility criteria for FINESSE-ANGIO mirror
hose for FINESSE (16). Internal review boards of all
nstitutions approved the study. All patients provided addi-
ional written informed consent.
The FINESSE study’s patients were randomly assigned
n a 1:1:1 ratio to receive half-dose reteplase plus abciximab
combination-facilitated PCI), abciximab alone (abciximab-
acilitated PCI), or placebo immediately following random-
zation with abciximab administered in the catheterization
aboratory after angiography in this group (primary PCI).
eparin was limited to 40 U/kg
ith a target activated clotting
ime of 200 to 250 s.
tudy procedures. Stent implan-
ation at the IRA lesion site was
trongly encouraged, but devices
o trap embolic materials and pre-
ent clot embolization or tech-
iques to aspirate the intracoro-
ary thrombus were discouraged.
fter stent implantation, drugs
uch as adenosine or calcium-
ntagonists that improve the con-
rast runoff of the epicardial ves-
els were permitted.
tudy end points. The primary
fficacy end point was the per-
entage of patients achieving
IMI flow grade 2/3 of the IRA at first angiography.
econdary efficacy end points included: 1) the percentage of
atients achieving TIMI flow grade 3 flow of the IRA; 2)
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Abbreviations
and Acronyms
cTFC  corrected TIMI
frame count
GP  glycoprotein
IRA  infarct-related artery
MBG  myocardial blush
grade
PCI  percutaneous
coronary intervention
QCA  quantitative coronary
angiography
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionccepted August 20, 2010.
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1286orrected TIMI frame count (cTFC (17); and 3) the
ercentage of patients achieving MBG 2 to 3. All pre-PCI
IMI flow, cTFC, and MBG assessments were to be done
efore wiring the lesion or passing any device. We also
valuated the primary and secondary clinical end points
rom the overall FINESSE study in the angiographic
ubstudy population (16).
ngiographic analysis. The quantitative coronary angiogra-
hy (QCA) analysis for TIMI flow, cTFC, and MBG was
erformed offline by the Rome Heart Research of the
oundation “Centro per la Lotta Contro l’Infarto,” Rome,
taly, with a computer-assisted system using an automated
dge-detection algorithm (MEDIS, Cardiovascular An-
iography Analysis System II, Pie Medical Data, Maas-
richt, the Netherlands) by observers blinded to treatment
ssignment. The QCA analysis of the IRA was performed on
asal, pre-intervention and post-intervention angiograms using
orthogonal views. Procedural guidelines for angiographic
mages included reproduction of baseline views, extended cine
uns for antegrade and collateral flow and MBG assessment,
nd use of intracoronary nitroglycerin.
tatistical analysis. The sample size was estimated assuming a
0% pre-intervention TIMI flow grade 3 rate in the IRA
ithout pre-angiography use of abciximab (8,11). An approach
ased on the pre-PCI use of upstream abciximab would lead to
projected pre-intervention TIMI flow grade 3 rate of 30%
nd for combination-facilitated PCI patients, 60%.
A sample size of 626 patients was needed to obtain a 90%
hance of detecting an absolute difference of 30% in the
rimary efficacy variable between the abciximab-facilitated and
ombination-facilitated PCI groups, and an absolute difference
f 20% between primary and abciximab-facilitated PCI groups,
ith 80% power and a 2-sided alpha error of 5%.
The primary efficacy variable and all other noncontinuous
ngiographic variables were analyzed using the chi-square
est or the Fisher exact test. The cTFC and other contin-
ous variables were analyzed using an analysis of variance or
he Mann-Whitney U test. Bonferroni correction was ap-
lied for multiple comparisons. A p value of 0.05 was
onsidered significant. Analyses were performed with SAS
oftware (version 8.02, SAS Institute Inc., Cary, North
arolina).
esults
f the 2,452 FINESSE patients enrolled between August
002 and December 2006, 637 were included in the
INESSE-ANGIO substudy (213 in the combination-
acilitated, 222 in the abciximab-facilitated, and 202 in the
rimary PCI groups). The overall median time from qual-
fying electrocardiogram to first study-drug administration
as 41 min; the median time from first study-drug admin-stration to first angiography was 55 min. pAnalyzable pre-PCI TIMI flow grade, cTFC, and MBG
ere obtained in 99.5%, 96.7%, and 97.8% of patients,
espectively. Analyzable post-PCI TIMI flow grade, cTFC,
nd MBG were available in 97.0%, 85.5%, and 91.2%,
espectively.
aseline characteristics. Baseline clinical characteristics and
nitial treatments received were similar across groups (Table 1).
he times from symptom onset to the start of reperfusion
herapy in the combination-facilitated, abciximab-
acilitated, and primary PCI groups were 3.5 1.4 h, 3.5
.5 h, and 3.5  1.6 h, respectively (p  NS for all).
oncomitant medication use in the first 24 h following
andomization was similar across groups, as was stenting,
hereas embolic protection device use was rare. Median
nfarct size estimated by creatine kinase curve analyses for
nterior MIs, stratified by treatment group were 1,756
U/l/h, 1,753 IU/l/h, and 1,865 IU/l/h for the combination-
acilitated, abciximab-facilitated, and primary PCI groups,
espectively. Angiographic QCA parameters were compa-
able across groups, except for a statistically higher pre-
rocedural minimal lumen diameter and a smaller steno-
is diameter in the combination-facilitated versus the
rimary PCI groups (Table 2). At hospital discharge, use of
ngiotensin-converting enzyme inhibitors and beta-blockers
as very common and equal across groups. Demographics
n this angiographic substudy were very similar to those for
INESSE patients not in the substudy, except a higher
ercentage of substudy patients had hypercholesterolemia
37.7% vs. 31.8%), used angiotensin-converting enzyme
nhibitors at baseline (81.2% vs. 77.3%), and were currently
moking (49.5% vs. 41.4%; all p  0.05).
rimary end point. The combination-facilitated group dem-
nstrated significantly higher rates of pre-procedural IRA
atency compared with the abciximab-facilitated and the
rimary PCI groups (76.1% vs. 43.7% and 32.7%, respec-
ively; p  0.0001 for both; abciximab-facilitated vs. pri-
ary PCI, p  0.025) (Fig. 1).
Improvement in vessel patency in the abciximab-facilitated
roup compared with the primary PCI group was due to a
ignificant increase in TIMI flow grade 2 rate whereas TIMI
ow grade 3 rate was similar in these groups; the higher
atency in the combination-facilitated group was driven
ainly by greater TIMI flow grade 3 rate (Table 3). A
ompletely occluded IRA (TIMI flow grade 0) at baseline
ngiography was found in 19.7% in the combination-
acilitated, 46.4% in the abciximab-facilitated, and 59.9% in
he primary-PCI groups (p  0.0001 among all groups). The
nvestigator-reported TIMI rates and the core laboratory rates
ere not distinctly dissimilar, with a kappa coefficient showing
n inter-rater agreement of 0.479, supporting the need for a core
aboratory to ensure consistency in large clinical studies.
econdary end points. Although pre-procedural secondary
nd point results differed significantly among all groups,
ost-procedural end point results were similar. TIMI flow
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1287rade 3 following PCI was observed in 79.8%, 77.7%, and
6.6% (p  0.6); MBG 2 to 3 was present in 85.6%, 79.5%,
nd 86.4% (p  0.7); and cTFC was 17.1  15.8, 17.4 
7.3, and 15.8  14.1 (p  0.3) in the combination-
acilitated, abciximab-facilitated, and primary-PCI groups,
espectively (Fig. 2).
Table 1. Baseline Clinical Characteristics
Characteristics
Primary PCI
(n  202)
Age, yrs 61.7 9.9
Men 139 (68.8)
Body mass index, kg/m2 26.7 3.7
Hypertension 94 (46.5)
Diabetes mellitus 32 (15.8)
Current smokers 143 (70.8)
Hypercholesterolemia 83 (41.1)
Previous MI 19 (9.4)
Previous CHF 6 (3.0)
Location of infarction*
Anterior 87 (43.0)
Inferior or posterior 88 (43.6)
Other 27 (13.4)
Interval from symptom onset to qualifying
ECG obtained in the ER, h
2.35 1.46
Door-to-balloon time, h 2.24 0.91
Use of embolic protection device 0
Use of intracoronary stent 188 (95.4)
Concomitant medication use†
Aspirin 196 (97.0)
Thienopyridine 186 (92.1)
Calcium-channel blocker 32 (15.8)
Vasopressor 11 (5.4)
Data presented as mean SD or n (%). Percentages may not sum to 100 due to rounding. *Some p
to 24 h after randomization.
CHF congestive heart failure; ECG electrocardiogram; ER emergency department; MIm
Table 2. Baseline Angiographic Characteristics: Angiographic Core Laborat
Variables
Primary PCI
(n  202)
IRA
LAD 96 (47.5)
LM 1 (0.5)
Circumﬂex 31 (15.3)
RCA 74 (36.6)
Pre-procedural RD, mm 2.6 0.7
Pre-procedural DS, % 90.3 12.9
Pre-procedural MLD, mm 0.27 0.38
Post-procedural DS, % 9.0 10.5
Post-procedural MLD, mm 2.7 0.6
Data presented as as n (%) or mean SD. *p 0.05 for the comparison with primary PCI.
DS diameter stenosis; LAD left anterior descending artery; LM left main artery; MLD reference diameter.ther efﬁcacy outcomes. In the FINESSE-ANGIO sub-
opulation, the FINESSE 90-day primary composite end
oint occurred in 6.6% of the combination-facilitatedPCI
roup, 5.4% of the abciximab-facilitatedPCI group, and
.9% of the primary-PCI group (hazard ratio for the
ombination-facilitated vs. the primary-PCI group: 1.18;
Abciximab-Facilitated PCI
(n  222)
Combination-Facilitated PCI
(n  213)
60.6 11.7 62.1 11.4
164 (73.9) 167 (78.4)
27.0 3.8 26.4 3.7
106 (47.7) 98 (46.0)
29 (13.0) 32 (15.0)
153 (68.9) 152 (71.4)
73 (32.9) 84 (39.4)
16 (7.2) 28 (13.1)
1 (0.5) 4 (1.9)
109 (49.1) 100 (47.0)
98 (44.1) 100 (46.9)
15 (6.8) 13 (6.1)
2.43 1.52 2.31 1.44
2.23 0.81 2.27 0.84
1 (0.5) 2 (0.9)
207 (94.1) 205 (96.7)
215 (96.8) 206 (96.7)
216 (97.3) 206 (96.7)
35 (15.8) 42 (19.7)
8 (3.6) 13 (6.1)
had an infarct that extended to more than 1 location. †During the period between randomization
al infarction; PCI percutaneous coronary intervention.
ata
Abciximab-Facilitated PCI
(n  222)
Combination-Facilitated PCI
(n  213)
111 (50) 96 (45.1)
0 0
23 (10.4) 34 (16)
88 (39.6) 83 (38.9)
2.7 0.7 2.7 0.6
87.9 13.9 79.1 14.9*
0.34 0.29 0.58 0.43*
10.1 12.8 8.6 12.0
2.7 0.6 2.7 0.6
l luminal diameter; PCI percutaneous coronary intervention; RCA right coronary artery; RDatientsory D
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12885% confidence interval: 0.58 to 1.35). Complications of
I occurred in 3.7%, 4.0%, and 4.0% of patients in the 3
roups, respectively, with no significant differences. The
ndividual components of the FINESSE primary end point
id not differ significantly among groups; the respective
ates were 2.8%, 1.3%, and 2.0% for all-cause mortality;
.8%, 2.7%, and 2.5% for cardiogenic shock; 0.9%, 1.3%,
nd 1.5% for rehospitalization or emergency department
isit for congestive heart failure; and no ventricular fibrilla-
ion occurred 48 h after randomization.
orrelation of TIMI ﬂow grade before PCI with outcome
ndependent of treatment. To explore the effect of pre-PCI
IMI flow grade status on outcome independent of treat-
ent, we pooled all treatment groups (Table 4). As ex-
ected, TIMI flow grade before PCI was inversely corre-
ated with adverse outcomes.
iscussion
he FINESSE-ANGIO substudy represents 1 of the largest,
ost rigorous efforts to clarify the effect of periprocedural
Figure 1. Rate of Patency at Angiography Performed at the Time
of Catheterization
Rate of patency (TIMI ﬂow grade 2/3) at angiography performed at the
time of catheterization. PCI  percutaneous coronary intervention;
TIMI  Thrombolysis In Myocardial Infarction.
Table 3. TIMI Flow Grade Comparisons
Variables
Primary PCI
(n  202)
Abciximab-Facilitated PCI
(n  222)
Combination-Fac
PCI (n  2
TIMI ﬂow grade 0, % 59.9 46.4 19.7
TIMI ﬂow grade 1, % 7.4 9.9 4.2
TIMI ﬂow grade 2, % 14.4 24.8 29.1
TIMI ﬂow grade 3, % 18.3 18.9 47.0Abcix abciximab; combo combination; PCI percutaneous coronary intervention; prim primary; Nntithrombotic therapy for primary angioplasty. In this sub-
tudy, we analyzed angiographic data from 637 patients en-
olled in the randomized, double-blind FINESSE study. Our
ain finding is that, in patients presenting with STEMI and
aving an expected delay of 1 h before angiography, early
reatment with abciximab alone or abciximab plus half-dose
eteplase resulted in higher IRA patency rates at baseline
oronary angiography compared with no pre-treatment
efore angiography. However, post-procedural angio-
raphic and microcirculatory variables were not affected by
acilitation therapy, when compared with standard treat-
ent using abciximab immediately before intervention.
hese data bring into question the value of pharmacological
re-treatment and pre-procedural versus post-procedural
ngiographic assessments both as predictors of outcomes
nd parameters of effective reperfusion.
Previous randomized trials investigated the benefits of the
arly administration of GP IIb/IIIa inhibitors in patients
ndergoing primary PCI (18–23). As the adjunctive use of
P IIb/IIIa inhibitors, mostly abciximab, has been shown
n both meta-analyses and prospective single studies to
educe mortality among patients undergoing primary PCI
24–26), further benefits by earlier drug administration were
xpected in terms of improved pre-procedural recanalization
nd myocardial reperfusion (27).
In our substudy, facilitation with abciximab alone had a
elatively modest effect on the pre-procedural IRA patency,
ith only a slight increase in TIMI flow grade 2 rate and no
ffect on TIMI flow grade 3 rate. Moreover, compared with
tandard administration before intervention, earlier treatment
sing abciximab in the emergency department or the spoke
ospital did not significantly improve any post-PCI variables
onsidered to represent better myocardial reperfusion, which is
eemed responsible for the beneficial effects of abciximab (28,29).
he patency rates observed in this study do, however, correlate
ith the degree of ST-segment resolution (70%) previously
eported in the overall trial at 60 to 90 min following randomiza-
ion, where the combination-facilitated group had a significantly
igher rate (43.9%) than the abciximab-facilitated (33.1%, p 
.01) or the primary PCI (31%, p  0.003) groups (17).
A possible reason for these negative findings is the long
elay (3 h) between symptom onset and start of abciximab in
d
p Value
Prim PCI vs. Abcix
Facilitated
Prim PCI vs. Combo
Facilitated
Abcix-Facil. vs. Combo
Facilitated
0.007 0.0001 0.0001
NS NS 0.04
0.009 0.0001 NS
NS 0.0001 0.0001ilitate
13)S not significant; TIMI Thrombolysis In Myocardial Infarction.
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1289he FINESSE study, which is possibly too long for an
ntiplatelet agent to show significant benefit. As shown in an
nalysis of in-ambulance use of abciximab in the Bologna
TEMI network, earlier administration of abciximab (2-h
Figure 2. TIMI Flow Grade, cTFC, and MBG Before and
After Intervention
(A) Percent of patients achieving TIMI ﬂow grade 3 at angiography per-
formed before and after intervention; (B) values of corrected TIMI frame
count before and after intervention; (C) percent of patients achieving myo-
cardial blush grade 2/3 before and after intervention. cTFC  corrected
TIMI frame count; MBG  myocardial blush grade; other abbreviations as in
Figure 1.edian time from symptom onset to administration) mayesult in an improved outcome (30). The presence of a
ignificant time interval between facilitation and PCI is an-
ther possible reason. In the FINESSE study, although the
olus of abciximab was administered early, the infusion was not
tarted until after PCI, unlike the steady infusion started
irectly after the abciximab bolus in the EUROTRANSFER
egistry. This difference in approach may have diminished
re-intervention TIMI flow grade 3 rates and myocardial
alvage (31–33). A much more effective method of achieving
arly patency of the IRA is fibrinolytic therapy using a
brin-specific agent able to improve TIMI flow grade after 60
o 90 min. However, previous attempts to reopen the IRA using
fibrinolytic agent upstream of PCI were completely negative,
ossibly due to platelet activation by fibrinolytic therapy thereby
romoting rethrombosis and increasing the risk of early ischemic
vents, as shown in the PACT (Plasminogen Activator-
ngioplasty Compatibility Trial) (34) and the ASSENT-IV PCI
Primary versus tenecteplase-facilitated percutaneous coronary in-
ervention in patients with ST-segment elevation acute myocar-
ial infarction): randomized trial (35).
The antiplatelet/fibrinolytic cocktail with abciximab and
alf-dose reteplase tested in FINESSE exploited the powerful
brinolytic effect of reteplase without initiating subsequent
emostatic activation by combining it with a powerful anti-
latelet agent. Preliminary data from both TIMI 14 (Throm-
olysis In Myocardial Infarction Trial, Phase 14) and SPEED
Strategy for Patency Enhancement in the Emergency Depart-
ent Group) studies were highly encouraging, showing TIMI
ow grade 3 of 60% to 70% at 60 to 90 min in the IRA (13,14).
n terms of clinical efficacy, this strategy proved only partially
ffective in FINESSE. As expected, the pro-ischemic events
ypically associated with fibrinolytic therapy were ameliorated
ith concomitant abciximab use, although only a modest trend
oward a reduction of STEMI complications and no reduction
n mortality was seen, possibly due to an increased risk of
leeding (16). The FINESSE-ANGIO data confirm that this
ombination-facilitated therapy is able to provide a high rate of
atency in the IRA during transportation of the patient to the
atheterization laboratory, with 47% of patients achieving
IMI flow grade 3 and another 29% achieving TIMI flow
rade 2. This effect may have provided better hemodynamic
tatus and a more expedited PCI procedure in high-risk
atients, such as those with large myocardial infarctions, resulting
Table 4. Effect of Pre-PCI TIMI Flow Grade on Efficacy Outcomes:
Pooled Analysis
Variables Primary End Point 90-Day Mortality 1-Year Mortality
TIMI ﬂow grade missing 0% 0% 0%
TIMI ﬂow grade 0 7.5% 3.8% 4.5%
TIMI ﬂow grade 1 7.0% 0% 0%
TIMI ﬂow grade 2 6.8% 0% 0.7%
TIMI ﬂow grade 3 2.8% 1.7% 1.7%Abbreviations as in Tables 1 and 3.
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1290n smaller infarct size as shown by area under the curve analysis of
reatine kinase release (16,36).
However, no advantage in terms of post-procedural myo-
ardial perfusion indexes was observed with combination-
acilitation compared with facilitation with abciximab alone.
ne should keep in mind that the control treatment, that is,
bciximab immediately before PCI, has itself been shown to
mprove myocardial perfusion indexes (13,14) and thus earlier
pstream reperfusion therapy may not offer further improve-
ent. Thus, although combination therapy has been highly
ffective in recanalizing the IRA before intervention without
he risk of rebound ischemia associated with fibrinolytic treat-
ent, this improvement in pre-procedural flow was not asso-
iated with better post-procedural flow and provided only
arginal improvement in myocardial salvage. Also with regard
o combination-facilitated therapy, the delay in drug delivery in
he FINESSE study may have decreased the likelihood of
yocardial salvage. In a recent post hoc analysis of the
INESSE study, clinical benefit appeared to be restricted to
igher risk patients enrolled within 4 h of symptom onset at
ites without PCI capabilities requiring transfer. In these
atients, first door-to-balloon times were longer and the
reatest benefit of increased early reperfusion from combina-
ion therapy might be expected (37).
Our findings may contrast those reported by Stone et al.
33) and Brodie et al. (38) supporting the prognostic role of
re-procedural flow in primary angioplasty. Besides the PACT
34) and ASSENT-IV PCI studies (35), other studies of
re-procedural reperfusion therapy (39,40) have failed to show
mprovement in post-PCI clinical outcomes despite a signifi-
antly higher initial patency rate (41). Thus, in primary PCI,
harmacologically enhanced pre-procedural patency may not
quate to spontaneous patency due to mechanisms not yet
nderstood. These data are supported by the pooled analysis
Table 4) similarly demonstrating that higher pre-PCI TIMI
ow grades were associated with better clinical outcomes overall.
onclusions
rimary PCI preceded by pre-catheterization treatment
ith abciximab alone, and especially with abciximab plus
alf-dose reteplase, resulted in higher IRA patency rates
t baseline coronary angiography compared with standard
rimary PCI. However, post-procedural patency and
ngiographic indexes of myocardial reperfusion were not
mproved by facilitation strategies compared with abcix-
mab administered immediately before intervention. In
atients in this substudy, early reperfusion did not
mprove clinical outcomes. Whether clinical benefit cor-
elated with pharmacologically induced or improved pre-
CI myocardial reperfusion may be restricted to higher-
isk subsets (36,37) remains to be determined by future
rospective studies.cknowledgments
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